From The Helm: Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer The Bellcast podcast

Artwork

Trading Business Bell Direct Online Share Trading Ausbiz Asx200 Investing Economics

Innhold levert av Bell Direct. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Bell Direct eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

The Bellcast « »
From the helm: Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer

4y ago 5:57

Del

MP3•Episoder hjem

Innhold levert av Bell Direct. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Bell Direct eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer.
Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC's US journey gathers momentum with USFDA approval looming. The US is home to the world's largest nuclear medicine market.
In this video James discusses:
- (0:31) What CYC does & its "imminent" entry into the US
- (1:11) Key catalysts to drive share price growth
- (1:47) Commercialising the product in the US
- (2:46) CYC's product being endorsed to help fight COVID-19 in the US
- (3:31) How the company has reduced its risks
- (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

… continue reading

57 episoder

#Trading #Business #Bell Direct #Online Share Trading #Ausbiz #Asx200 #Investing #Economics

Artwork

From the helm: Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer

published 4y ago

Del

MP3•Episoder hjem

Innhold levert av Bell Direct. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Bell Direct eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm's (ASX:CYC) MD & CEO, James McBrayer.
Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC's US journey gathers momentum with USFDA approval looming. The US is home to the world's largest nuclear medicine market.
In this video James discusses:
- (0:31) What CYC does & its "imminent" entry into the US
- (1:11) Key catalysts to drive share price growth
- (1:47) Commercialising the product in the US
- (2:46) CYC's product being endorsed to help fight COVID-19 in the US
- (3:31) How the company has reduced its risks
- (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

… continue reading

57 episoder

#Trading #Business #Bell Direct #Online Share Trading #Ausbiz #Asx200 #Investing #Economics

Alle episoder

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema